Showing results (211-220 of 410) with videos related to
Sort By:
Pageof 41
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.Cancer Research Communications|March 2, 2023
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized LeukoplakiaGlenn J Hanna, Alessandro Villa, Nikhil Mistry, et al.Cancer Research Communications|March 6, 2023
Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized LeukoplakiaGlenn J Hanna, Alessandro Villa, Nikhil Mistry, et al.Cancer Cell|February 11, 2025
Genomic mediators of acquired resistance to immunotherapy in metastatic melanomaJulia Schiantarelli, Mouadh Benamar, Jihye Park, et al.Proceedings of the National Academy of Sciences of the United States of America|March 11, 2003
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destructionJan C Schmollinger, Robert H Vonderheide, Kara M Hoar, et al.Cancer Immunology Research|August 14, 2021
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced MelanomaF Stephen Hodi, Jedd D Wolchok, Dirk Schadendorf, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasFunda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.Frontiers in Oncology|May 27, 2024
Case report: Regression of in-transit metastases of cutaneous squamous cell carcinoma with combination pembrolizumab and topical diphencyproneDina Poplausky, Jade N Young, Brandon R Block, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.Pageof 41